ESTRO 2024 - Abstract Book

S1619

Clinical - Lung

ESTRO 2024

Conclusion:

Most patients receiving radiation for breast, mediastinal or thoracic tumors who use CPAP-RT/SBRT to manage respiratory motion tolerate treatment without complication. Treatment interruptions occurred mainly in patients receiving concomitant CTX-RT. Further research to optimize patient selection and develop strategies to minimize treatment interruptions will facilitate better use of this technique.

Keywords: motion manegment, SBRT, CPAP

722

Poster Discussion

Standard versus highly hypofractionated tumor irradiation in LA-NSCLC with durvalumab consolidation

Benoît Allignet 1,2 , Arnaud Colomb 1 , Guillaume Beldjoudi 1 , Maurice Pérol 3 , Lionel Falchero 4 , Vanina Isnardi 5 , Myriam Ayadi-Zahra 1 , Coralie Moncharmont 1 , Ronan Tanguy 1 , Line Claude 1 , Waisse Waissi 1 , Isabelle Martel-Lafay 1 1 Centre Léon Bérard, Radiation Oncology, Lyon, France. 2 Université de Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5220, Inserm U1294, CREATIS, Lyon, France. 3 Centre Léon Bérard, Medical Oncology, Lyon, France. 4 Hôpital Nord-Ouest, Pneumology and Thoracic Oncology, Villefrance-Sur-Saône, France. 5 Centre Léon Bérard, Nuclear Medicine, Lyon, France

Purpose/Objective:

In unresectable locally advanced NSCLC (LA-NSCLC), tumor SBRT (T-SBRT) showed promising results compared to normofractionated irradiation [1]. Nevertheless, data are scarce using this high dose treatment before durvalumab